River Global Investors LLP Buys 1,190,630 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

River Global Investors LLP increased its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 57.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,253,192 shares of the company’s stock after buying an additional 1,190,630 shares during the quarter. MaxCyte comprises approximately 2.6% of River Global Investors LLP’s investment portfolio, making the stock its 12th biggest position. River Global Investors LLP owned about 3.08% of MaxCyte worth $13,494,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Mudita Advisors LLP grew its holdings in shares of MaxCyte by 5.6% during the 3rd quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock worth $12,267,000 after purchasing an additional 167,101 shares in the last quarter. Geode Capital Management LLC grew its stake in MaxCyte by 2.0% during the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after buying an additional 47,960 shares in the last quarter. State Street Corp increased its holdings in MaxCyte by 5.1% in the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company’s stock valued at $8,827,000 after buying an additional 111,066 shares during the period. ArrowMark Colorado Holdings LLC raised its position in shares of MaxCyte by 13.8% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock valued at $5,426,000 after buying an additional 169,250 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC lifted its holdings in shares of MaxCyte by 0.6% during the 4th quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company’s stock worth $5,574,000 after acquiring an additional 7,781 shares during the period. Institutional investors own 68.81% of the company’s stock.

MaxCyte Stock Performance

NASDAQ MXCT opened at $3.51 on Friday. MaxCyte, Inc. has a 1 year low of $3.16 and a 1 year high of $5.26. The firm has a market capitalization of $371.92 million, a price-to-earnings ratio of -10.32 and a beta of 1.35. The firm’s 50 day simple moving average is $4.26 and its 200 day simple moving average is $4.00.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.